Funded Biotechnology Startups in Gaithersburg
Gaithersburg, Maryland has a notable concentration of biotechnology companies drawing capital across multiple round stages.
Gaithersburg, Maryland has a notable concentration of biotechnology companies drawing capital across multiple round stages. Among the 12 most recently funded companies in this segment, disclosed round sizes span from $250K — raised by Polaris Genomics (August 2025) and HeMemics Biotechnologies (March 2025) — to $130M closed by Cartesian Therapeutics in July 2024. Arcellx ($100M, December 2022) and Georgiamune ($75M, August 2023) round out the largest disclosed raises in this set.
Therapeutics-focused companies dominate this cohort, with multiple firms working in cell and gene therapy, RNA interference (Sirnaomics), and immunology (TeraImmune, Georgiamune). Round type transparency is limited — the majority of rounds are logged as Series Unknown — though labeled Series A activity appears with Certify Health (May 2025, undisclosed) and Georgiamune ($75M). Activity has continued into 2025, with four rounds closing between March and August of that year.
Most recent rounds
12 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Gaithersburg biotechs in this data?
Cartesian Therapeutics closed the largest round at $130M in July 2024, followed by Arcellx at $100M in December 2022 and Georgiamune at $75M in August 2023. Sensei Biotherapeutics ($30M Series B, January 2021) and Remedy Plan Therapeutics ($18M, May 2025) are the next largest disclosed amounts.
Which Gaithersburg biotech companies have raised most recently?
Polaris Genomics closed a $250K round on August 26, 2025, making it the most recent in this set. Certify Health (Series A, undisclosed) and Remedy Plan Therapeutics ($18M) both closed rounds on May 13, 2025. HeMemics Biotechnologies also raised $250K in March 2025.
How are round stages distributed across these 12 companies?
Eight of the 12 rounds are classified as Series Unknown. Of the labeled rounds, two are Series A (Certify Health, Georgiamune), one is Seed (Amplexd Therapeutics, $2M), and one is Series B (Sensei Biotherapeutics, $30M).
What therapeutic focus areas appear most often in this Gaithersburg cohort?
RNA interference is represented by Sirnaomics ($8M, October 2024), while cell and gene therapy companies include Cartesian Therapeutics ($130M) and Arcellx ($100M). Immunology-focused companies include Georgiamune ($75M Series A) and TeraImmune ($3M), consistent with Gaithersburg's position in the Maryland I-270 biotech corridor.
How has funding activity been distributed across years in this dataset?
2024 and 2025 (through August) each account for four rounds in this set. 2022 contributed two rounds — TeraImmune and Arcellx, both closing in December — while 2023 produced one (Georgiamune's $75M Series A) and 2021 one (Sensei Biotherapeutics' $30M Series B).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.